The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XOMA | -8.23% | -8.43% | -1.75% | -99% |
| S&P | +12.94% | +86.25% | +13.25% | +2,610% |
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
The key to big gains last year? Start off small.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.35M | 29.9% |
| Gross Profit | $8.47M | 17.8% |
| Gross Margin | 90.59% | -9.4% |
| Market Cap | $465.86M | 50.3% |
| Market Cap / Employee | $35.84M | 0.0% |
| Employees | 13 | 0.0% |
| Net Income | $10.35M | 160.0% |
| EBITDA | -$0.45M | 72.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $90.48M | -36.3% |
| Accounts Receivable | $3.57M | 241.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $115.06M | 5.9% |
| Short Term Debt | $16.85M | 64.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.43% | 23.7% |
| Return On Invested Capital | -4.63% | -0.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.30M | 96.6% |
| Operating Free Cash Flow | -$0.30M | 96.6% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 51.70 | - | |||
| Price to Book | 3.64 | 2.91 | 3.56 | 6.42 | 74.88% |
| Price to Sales | 10.93 | 8.26 | 9.96 | 14.84 | 3.40% |
| Price to Tangible Book Value | 3.64 | 4.26 | 5.09 | 17.25 | 369.67% |
| Enterprise Value to EBITDA | -10.79 | 57.88 | 94.71 | -1686.97 | 864.87% |
| Return on Equity | -16.2% | -3.4% | -12.4% | 16.2% | -151.65% |
| Total Debt | $119.20M | $114.45M | $114.58M | $131.91M | 10.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
